Research programme: heat-shock factor 1 pathway inhibitors - The Institute of Cancer Research
Latest Information Update: 16 May 2016
At a glance
- Originator The Institute of Cancer Research
- Class Small molecules
- Mechanism of Action Heat-shock protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 05 May 2016 Early research in Cancer in United Kingdom (unspecified route)